Kornimate/medical-research-clean huggingface dataset:
evaluation of meibomian gland dysfunction in chinese old patients

Conditions: Dry Eye

Summary: the purpose of this study is to identify age-related changes in chinese meibomian glands that may be associated with meibomian gland dysfunction (mgd).


Eligibility criteria:
inclusion criteria: * have dry eye symptom * have meibomian gland dysfunction exclusion criteria: * diabetes * history of ocular surgery * systemic disease or inflammation

Keywords: aged meibomian glands dry eye elderly
study on neurocognitive plasticity in patients with focal and drug-resistant epilepsy

Conditions: Epilepsy

Summary: this study consist of define anatomo-functional reorganization (plasticity) profiles for the mentioned cognitive functions, before surgery (chronic plasticity induced by the epileptogenic zone) in patients with drug-resistant epilepsy. for that, patients will have 2 mri examinations, one before surgery and the second, between 3 and 8 months after surgery.


Eligibility criteria:
inclusion criteria: * patients with diagnosis of pharmaco-resistant focal epilepsy * patient candidate for surgery to resect the epileptogenic zone * patients affiliated to a social security scheme or beneficiaries of such a scheme * patients with french as their mother tongue * patients who have given signed informed consent before performing any procedure related to the study. exclusion criteria: * contraindication to performing an mri: * intellectual disability objectified by a mini mental score (mms) score \<24 in the year preceding inclusion, * existence of a severe condition in general: cardiac, respiratory, hematological, renal, hepatic, cancerous, * participation in other research protocols underway with exclusion period or in the previous week, * persons referred to in articles l1121-5 to l1121-8 of the public health code.
evaluation of delirium prevention in critically ill patients

Conditions: Delirium

Summary: haloperidol is prescribed in high risk icu patients concerning delirium (50% or more chance to develop delirium detected with the delirium prediction model pre-deliric, or patients with history of dementia or alcohol abuse)since the delirium protocol is changed and haloperidol is added as a prevention treatment we are gathering information what the effect is on several aspects of delirium

measurement the effect of haloperidol as delirium preventive intervention. determining effect on: - delirium incidence in the icu - different subtypes of delirium - delirium free days in 28 days - days on the ventilator - length of stay on the icu and in-hospital - 28-day mortality - incidence of unexpected removal of tubes, and effect between different groups of patients. safety of haloperidol concerning qt-time, extrapyramidal symptoms. data are compared with the data of a historical cohort

Eligibility criteria:
inclusion criteria: * patients with predicted delirium chance of \>50% or history of dementia or alcohol abuse and treated with haloperidol exclusion criteria: * cam-icu is not applicable * patients admitted 24hours or shorter on the icu, patients who are delirious within 24 hours after icu admission * patients whereby haloperidol is contra-indicated

Keywords: delirium prevention critical care haloperidol
ranolazine for the treatment of chest pain in hcm patients

Conditions: Hypertrophic Cardiomyopathy

Summary: the purpose of rhyme is to evaluate the safety and efficacy of ranolazine in hypertrophic cardiomypathy patients with chest pain or dyspnea despite treatment with standard medical therapy. this is a small, pilot, open-label (non-randomized) study of an approved drug for the treatment of angina in a novel patient population (adult patient population with hypertrophic cardiomyopathy).


Eligibility criteria:
inclusion criteria: * age 18 years or older * left ventricle wall thickness \>/= 15mm in the absence of other condition causing hypertrophy * baseline angina/shortness of breath frequency of \> 2 episodes per week * willing to provide informed consent exclusion criteria: * severe stenotic valvular disease * severe valvular regurgitation except mitral regurgitation due to systolic anterior motion * significant (\>60% stenosis) coronary artery disease * acute coronary syndrome within 30 days * severe heart failure defined as lv systolic dysfunction with ejection fraction \<40% or nyha class 4 symptoms * severe renal impairment (glomerular filtration rate, \<30 ml/min/1.73 m2) * moderate-severe hepatic impairment (child-pugh classes b and c) * hospitalization for cardiac reason within 3 months of enrollment * anticipated changes to treatment of hcm within study period, including medications, device implantation, or septal reduction therapies * concomitant use of ketoconazole, macrolide antibiotics, and hiv protease inhibitors * active myocarditis, pericarditis, or restrictive cardiomyopathy * non-cardiac terminal illness with expected survival less than 6 months * women who are of childbearing potential * inability to perform or adhere to study protocol

Keywords: chest pain dyspnea
open, multicentric, prospective, quality of life study in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: to evaluate the evolution of the impact on daily life activities over the first 12 months following the introduction of interferon beta-1b treatment in patients presenting rrms or patients at high risk of developing multiple sclerosis after a first clinical demyelinating event


Eligibility criteria:
inclusion criteria: * males or females aged 18 years or over, having received a confirmed diagnosis of rrms as defined by the macdonald or poser criteria or after a first clinical demyelinating event suggestive of multiple sclerosis, and meeting the requirements of the study inclusion criteria * the choice of treatment must be clearly dissociated from the decision to include the patient in the study.

Keywords: multiple sclerosis quality of life
investigating the association of shock index and hemoglobin variation with postpartum hemorrhage after vaginal deliveries

Conditions: Postpartum Hemorrhage

Summary: postpartum hemorrhage (pph) is a leading cause of maternal mortality and morbidity, and is most commonly caused by poor uterine tone after delivery of the baby and placenta. currently, a lack of early identification of pph also results in delayed treatment, with an increase in morbidity. the investigators propose that 2 non-invasive methods may provide monitoring for early and accurate detection of pph. these methods include shock index (si) and continuous hemoglobin (hb) monitoring. si is defined as heart rate divided by systolic blood pressure, and can be used as a marker to predict the severity of hypovolemic shock. continuous hb monitoring can now be done using a non-invasive probe that is placed on the patient's finger. it provides real-time hb values, rather than having to draw blood and wait for a lab test. the investigators hypothesize that si will have a stronger association with postpartum blood loss than hb variation.

the investigators believe that trends in patient-specific si combined with continuous sphb monitoring, will be useful to identify pph and the immediate need for pharmacotherapy, as well as the need for transfusion in obstetric patients undergoing vaginal deliveries. the investigators expect shock index to increase and sphb levels to decrease with increasing blood loss after delivery. the compensatory hemodynamic response may start early, however, hb variation may be delayed unless the patient is transfused with crystalloids. also autotransfusion after delivery may influence these measures. it is unknown which one of the two indicators, si or sphb, has a stronger association with blood loss after vaginal delivery. it is already established that both si and sphb are independent, clinically useful markers indicating significant blood loss in elective cesarean delivery and trauma. this study would assess their utility in the recognition and management of obstetric hemorrhage following normal vaginal delivery, where early recognition and resuscitation reduces the risk of progressing to hemorrhagic shock, disseminated intravascular coagulation and death.

Eligibility criteria:
inclusion criteria: * patients who give written consent to participate in this study * all term laboring patients including spontaneous and induced labor (gestational age \>37 weeks) undergoing spontaneous vaginal delivery or instrumental delivery exclusion criteria * patients who refuse to give written informed consent * patients with cardiac rhythm abnormalities or cardiac diseases * patients undergoing elective/emergency cd * patients with jaundice * patients with abnormal hb--\>such as sickle cell disease and thalassemia * patients with peripheral vascular disease * patients with hypertension and preeclampsia * patients on medications affecting blood pressure such as anti hypertensives (including magnesium sulphate), and those affecting hr (including beta blockers)

Keywords: pregnancy postpartum hemorrhage vaginal delivery shock index hemoglobin
daptomycin in the treatment of subjects with infective endocarditis or bacteremia due to s. aureus

Conditions: Bacterial Endocarditis; Bacteremia

Summary: the purpose of this study is to compare the safety and efficacy of daptomycin, an antibiotic, to standard therapy in subjects who have infective endocarditis or bacteremia due to staphylococcus aureus (s. aureus).

even with prompt treatment, staphylococcus aureus infective endocarditis (ie) continues to be associated with significant morbidity and mortality indicating a need for new therapeutic approaches. in vitro, daptomycin is rapidly bactericidal, with concentration-dependent killing, and mic90 of 0.5 microgram/ml for s. aureus; in clinical studies, daptomycin appears to be well tolerated and can be administered once every 24 hours by i.v. infusion. these characteristics suggest it should be clinically and microbiologically effective in the treatment of serious s. aureus infections, including ie and bacteremia comparison: standard of care (vancomycin or semi-synthetic penicillin with adjunct gentamicin)

Eligibility criteria:
inclusion criteria: * documented s. aureus bacteremia within 2 calendar days of the first dose of study medication exclusion criteria: * subjects with a creatinine clearance of less than 30 ml/min * subjects with pneumonia * pregnant, nursing, or lactating * documented history of allergy or intolerance to penicillin or vancomycin * subjects with osteomyelitis

Keywords: gram-positive bacterial infections staph aureus endocarditis bacteremia cubist
predictors of depression treatment response to exercise

Conditions: Depression; Major Depressive Disorder

Summary: 50 subjects with major depressive disorder who are not currently receiving treatment will be enrolled in a 12-week exercise program, supervised by a trained exercise interventionist.

50 subjects with major depressive disorder who are not currently receiving treatment will be enrolled in a 12-week exercise program, supervised by a trained exercise interventionist. blood samples will be collected at baseline for analysis of inflammatory cytokines, as well as other potential biological predictors of treatment outcomes (i.e., bdnf). assessments will gather data on potential clinical predictors of treatment outcomes (anxiety, stress, sleep). assessments and sample collection will also occur at 3 time points during the treatment period (weeks 4, 8, and 12) to identify mediators and correlates of treatment effects.

Eligibility criteria:
inclusion criteria: 1. diagnosed with mdd 2. ages 18-65 will be included. 3. ability to understand and willingness to provide written informed consent. 4. willing to provide contact information. 5. medical clearance with protocol-defined stress testing (in accordance with american college of sports medicine (acsm) guidelines) from protocol approved medical personnel. details of guidelines and related testing protocol are provided in the study manual of procedures. 6. able to comprehend and communicate in english. exclusion criteria: 1. have a medical condition contraindicating exercise participation 2. are currently physically active - defined as moderate intensity physical activity on 3 or more days per week for the last month 3. currently receiving antidepressant medication treatment 4. currently considered a high suicide risk and/or high risk for being unable to complete the study due to the need for psychiatric hospitalization, suicide attempts or suicidality, significant self-mutilation, or other self-injurious or destructive behavior based on the judgment of the site pi, medical personnel, or designee. 5. pregnancy. 6. current psychotic disorder. other comorbid psychiatric diagnosis that, in the investigator's judgment, will pose a safety issue or make it difficult for the participant to understand or complete the intervention. 7. anticipated circumstances over the 6-month course of the trial that would render the participant unlikely to complete the study in the judgment of the pi or designee. 8. any reason not listed herein yet, determined by the pi, medical personnel, or designee that constitutes good clinical practice and that would in the opinion of the pi, medical personnel, or designee make participation in the study hazardous. 9. are currently enrolled in another research study, and participation in that study contraindicates participation in the current study
application of psychiatric knowledge in the rehabilitation process in return to work.

Conditions: Mental Disorders

Summary: the hypothesis was that education of rehabilitation officers who were responsible for rehabilitation back to work for sick-listed individuals in screening for mental disorders and psychiatric topics would increase the rate of return to work and reduce the number of sicklisted days


Eligibility criteria:
inclusion criteria: * sick-listed and belonging to the case-load of rehabilitation officers who participated in the intervention exclusion criteria: * no

Keywords: sickness absence rehabilitation mental disorders screening
efficacy and safety of farletuzumab (morab-003) in combination with carboplatin and taxane in participants with platinum-sensitive ovarian cancer in first relapse

Conditions: Ovarian Cancer

Summary: this research is being done to find out if carboplatin and taxane works better alone or when given with an experimental drug called morab-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.


Eligibility criteria:
inclusion criteria: * a histologically or cytologically confirmed diagnosis of non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies * must have measurable disease by ct or mri scan * must have relapsed radiologically with a randomization date within ≥6 and \< 24 months of completion of first-line platinum chemotherapy * have been treated with debulking surgery and first-line platinum and taxane based chemotherapy. * prior bevacizumbab maintenance is allowed. the last dose of bevacizumab must have been at least 30 days before study day 1. no cytotoxic maintenance therapy (e.g. taxane) or cancer vaccine therapy is allowed. * must be a candidate for carboplatin and taxane therapy * neurologic function: neuropathy (sensory and motor) ≤ctcae grade 1 exclusion criteria: * subjects who never responded to first-line platinum-based therapy or whose first relapse occurs \ 24 months from the last platinum therapy * subjects who have received other therapy to treat their ovarian cancer since relapse * known central nervous system (cns) tumor involvement * evidence of other active invasive malignancy requiring treatment in the past 5 years * known allergic reaction to a prior monoclonal antibody therapy or have any documented haha * previous treatment with morab-003 (farletuzumab) * clinical contraindications to use of a taxane

Keywords: ovarian cancer relapsed ovarian cancer platinum-sensitive ovarian cancer
incidence of retinopathy and associated risk factors in children and young adults with type 1 diabetes in denmark

Conditions: Type 1 Diabetes; Diabetic Retinopathy

Summary: the objective of this study is to clarify the current diabetic status, including development of complications, in a nationwide cohort of type 1 diabetics, who were last examined together in a large study in 1995. these youngsters were originally participating in a nationwide study of children with type 1 diabetes in denmark back in 1986. the investigators will try to establish risk factors for developing diabetic retinopathy. the investigators will have emphasis on retinal vessel geometry and the possibilities for early detection of reversible retinal changes, and prediction of other vascular complications.


Eligibility criteria:
inclusion criteria: * participation in the follow-up study in 1995 exclusion criteria: * no retinal photographs from 1995
effect of 12 weeks treatment with tadalafil vs placebo on lower urinary tract symptoms

Conditions: Prostatic Hyperplasia; Lower Urinary Tract Symptoms

Summary: at present time several preclinical and clinical study have demonstrated the safety and efficacy of pde5 (phosphodiesterase type 5)-inhibitors for luts/bph (lower urinary tract symptoms/benign prostatic hyperplasia) patients with or without erectile dysfunction. however, the link between clinical outcomes (symptoms scores), functional activity (urodynamic findings) and molecular pathways, in particular regarding inflammatory pattern (molecular analyses), has not been previously investigated. aim of present study is to assess, for the first time in literature, changes in pressure flow study (pfs) and changes in molecular profile of prostatic tissue (inflammatory and tissue remodeling markers) in men treated for 12 weeks with tadalafil 5 mg compared with placebo and to correlate these data with changes in symptoms scores (ipss, international prostatic symptoms score) in men with luts secondary to bph refractory to alpha blockers.


Eligibility criteria:
inclusion criteria: * adult male subjects planned to undergo simple prostatectomy (turp, transurethral resection of the prostate, or open prostatectomy) for benign prostatic hyperplasia; * treatment with alpha-blockers (tamsulosin 0.4 mg/die) * being capable of giving informed consent. exclusion criteria: * participation in another clinical study; * known or suspected presence of prostatic cancer or psa (prostate specific antigen) value \>10 ng/ml; * suspected lack of the participant's compliance; * known severe allergies or hypersensitivity to the study drug (active substance or excipients of the formulation); * nown neurogenic bladder (i.e. parkinson's disease); * suspected or proven urinary infections; * presence of bladder stone.

Keywords: phosphodiesterase 5 inhibitors bph/luts
azd5672 bioavailability study in healthy male and female subjects

Conditions: Rheumatoid Arthritis

Summary: the aim of this study is to compare the blood levels achieved with a new formulation of azd5672 to an existing formulation of azd5672 used in previous studies


Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study-specific procedures * bmi between 18 and 30 kg/m2 * medical and surgical history and physical examination without any clinically significant findings * non smokers or past smokers who have stopped smoking within the last 6 months. exclusion criteria: * history of clinically significant cardio- or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder or any other major disorder that may interfere with the objectives of the study, as judged by the investigator * clinically significant illness as judged by the investigator, within two weeks before the first administration of investigational product. * female subjects who have a positive pregnancy test or who are pregnant or breast-feeding

Keywords: azd5672 relative bioavailability rheumatoid arthritis (ra)
a phase iv clinical trial to study the safety, tolerability and efficacy of tinefcon in patients with plaque psoriasis

Conditions: Plaque Psoriasis

Summary: psoriasis is a chronic inflammatory hyperproliferative disease of the skin affecting approximately 2% of the world's population.this phase iv study is planned to monitor performance of tinefcon in patients suffering from psoriasis under conditions of actual use and fulfill requirements to monitor all adverse drug reactions (adrs) in psoriasis patients treated with tinefcon. this study will add to literature on the risks and benefits of tinefcon the novel oral tnf-alpha release inhibitor.


Eligibility criteria:
inclusion criteria: * subjects of at least 18 years of age with clinical diagnosis of plaque psoriasis * subject who understand and willing to sign informed consent document before start of any study specific assessment exclusion criteria: * pregnant and lactating females * subject with active infection, acute or chronic due to bacteria, viruses, fungi or parasites (most notably tuberculosis, and chronic hepatitis b) * subject with heart failure (new york heart association class iii or iv) * subject with demyelinating disease * subject with solid cancer or hematologic malignancy diagnosed within last 5 years with a potential for progression * women of childbearing potential \[defined as a sexually mature woman who has not undergone hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e. who has had menses any time in the preceding 24 consecutive months)\] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) after signing an informed consent document (icd), during the duration of study participation and for at least 4 week after withdrawal from the study, unless they are surgically sterilized * subject with situations associated with a high risk of infection such as latent untreated tuberculosis, joint prosthesis infection within last 12 months, indwelling urinary catheter, uncontrolled diabetes, chronic obstructive pulmonary disease, skin ulcer * subject with known premalignant lesions (such as polyps in the colon or urinary bladder, cervical dysplasia and myelodysplasia) * subject known to be seropositive and/or clinically suspected to have the human immunodeficiency virus infection * subject with any condition that might make it difficult for the subject to participate in the study, at the discretion of the investigator.

Keywords: plaque psoriasis